All news (page 24)

• 

  19 May 2026

  Bilfinger wins £15m biopharma maintenance contract in Scotland

  3‑year maintenance contract (two 1‑yr extensions) at a strategic biopharma manufacturing site. ~60 trades transfer. Services: electrical, instrumentation, access, insulation, painting, plus shutdown/project support in GMP.
• 

  19 May 2026

  Statkraft to invest NOK 80bn in Norwegian hydropower over 10 years

  Half for major maintenance; rest for upgrades, new capacity and wind repowering. Nationwide dam reinforcements, turbine and tunnel refurbishments; projects need permits and profitability
• 

  18 May 2026

  Teijin Frontier expands OCTAIR™ insulation fiber capacity at Matsuyama Plant

  New equipment will boost OCTAIR™ output starting March 2027 to meet demand for down alternatives, targeting about 1,000 t/yr by 2030.
• 

  18 May 2026

  Boehringer Ingelheim's JASCAYD (nerandomilast) approved in Japan for IPF and PPF

  First oral PDE4B inhibitor shows slowed FVC decline in FIBRONEER Phase III; pooled analysis showed 59% nominal death reduction. Common AE: diarrhea; EU/UK reviews ongoing.
• 

  18 May 2026

  Dow launches Coolant Care Network for data center liquid cooling

  End-to-end coolant management for data centers: approved labs and service providers, centralized data review, expert analysis and field support to improve uptime and cut operational risk.
• 

  18 May 2026

  Genentech to present ASCO 2026 data on giredestrant in early ER+ breast cancer

  Presents data on nine drugs across 15+ indications: breast‑cancer first‑line/post‑progression analyses, HER2 brain‑penetrant TKI, KRAS G12C+pembrolizumab, and lymphoma ADC/bispecific combo

• 

  18 May 2026

  NRC Issues FONSI for Dow and X-energy Long Mott Nuclear Project in Texas

  NRC completed an Environmental Assessment and issued a FONSI for a proposed advanced SMR at Seadrift, Texas, clearing a key Construction Permit step to supply electricity and industrial steam.
• 

  18 May 2026

  SkyKraft awarded €21m Industriklivet grant for eSAF production in Skellefteå

  Funding will cover feasibility, design and engineering toward FID in 2027 for an eSAF plant targeting 130,000 t/yr using renewable power and biogenic CO₂, signaling market confidence.
• 

  18 May 2026

  Aramco and Pasqal launch Saudi Arabia’s first quantum computer and the Middle East’s first QCaaS platform

  Located in Dhahran, a 200-qubit neutral-atom QPU offers low-latency cloud access for industrial apps, enabling optimization, simulation and AI for energy, materials, logistics, CO2 storage; workforce training.
• 

  18 May 2026

  BASF opens refinery catalyst R&D center in Attapulgus, GA

  R&D center focuses on applied FCC testing, QA/QC and scale-up at production site to speed commercialization and tailor catalyst solutions to refiners
• 

  18 May 2026

  Essar Energy Transition completes Pre‑FEED for Stanlow Methanol‑to‑Jet SAF hub

  Planned plant will convert ~550,000 tpa renewable methanol into >200,000 tpa jet fuel, using existing refinery blending and pipeline export; FEED this year, FID by early 2028.
• 

  18 May 2026

  Merck: sac‑TMT meets OS and PFS endpoints in Phase 3 TroFuse‑005 for advanced/recurrent endometrial cancer

  TroFuse‑005 (776 pts) showed significant OS and PFS improvement vs chemotherapy in advanced/recurrent endometrial cancer after platinum and anti‑PD‑1/PD‑L1 therapy; ORR met; safety consistent.
• 

  18 May 2026

  Repsol and Santos begin Pikka oil production in Alaska

  Partners reached first oil at a North Slope project; production to hit 80,000 bpd plateau in Q3 with first sales then. 28 wells drilled in phase 1; 45 wells planned; further phases expected.
• 

  18 May 2026

  OMV starts production at Austria’s largest gas discovery in 40 years

  Wittau well begins gas output; first phase 11 TWh for winter 2026/27, recoverable up to 48 TWh. EUR150m invested so far; project could double Austria’s gas production.
• 

  18 May 2026

  Asahi Kasei Therapeutics starts Phase III trial of Teribone (teriparatide) for high‑risk osteoporosis

  Domestic Phase III trial to assess extended therapy beyond 24 months for patients with severe osteoporosis at high fracture risk; evaluates efficacy and safety of continued treatment.
• 

  18 May 2026

  Teijin Frontier and Asahi Kasei Advance form TA Frontier

  Merged firm launches Oct 1, 2026; ownership split 80/20. It combines materials technologies and marketing across textiles, industrial, building and resins for sustainable growth.
• 

  18 May 2026

  Chugai’s Alecensa Gets World-First Tumor‑Agnostic Approval for ALK‑Positive Solid Tumors

  Japan approves tumor‑agnostic ALK inhibitor for ALK‑fusion solid tumors including pediatrics. TACKLE Phase II showed 70–76% response in ALK‑fusion cases; safety consistent. FoundationOne CDx approved.
• 

  18 May 2026

  Chugai: MHLW approves FoundationOne CDx as Alecensa companion diagnostic for ALK‑positive solid tumors

  TACKLE Phase II supported Alecensa's efficacy/safety, enabling a partial marketing-authorization change; FoundationOne CDx expands tumor-agnostic genomic profiling and treatment options.
• 

  18 May 2026

  Seven MDBs Pledge Support for Middle East Conflict Impacts

  Offer financing, policy, private‑sector tools and technical assistance to manage shocks to energy, food and trade — providing relief, budget support, liquidity, trade finance, firm support and resilience investments
• 

  18 May 2026

  GSK’s Arexvy gains expanded approval in Japan for at‑risk adults 18–59

  Approval now explicitly includes immunocompromised adults; Phase IIIb showed non‑inferior immune response versus older adults and a safety profile consistent with prior trials.
• 

  15 May 2026

  PTT Global Chemical Q1 2026 Results: Integrated Value Chain Secures Production and Balances Portfolio

  Q1 revenue THB 146,936m; net profit THB 3,232m. Operations sustained via feedstock flexibility and supply‑chain continuity. Pivoting to specialty chemicals, bioplastics and recycled plastics.
• 

  15 May 2026

  Ercros Q1 2026: €13.6m loss

  Q1: contribution €52m; adj. EBITDA −€1m; liquidity €45m. Weak demand, high energy costs, non‑EU competition. Bondalti bid 77.23% accepted. New board aims to delist, restore profitability, integrate
• 

  15 May 2026

  Iberdrola completes phase 1 of Noronha Verde, installs 4,800 solar panels

  Project pairs solar with battery storage on Fernando de Noronha to reach 22 MWp/49 MWh, replace biodiesel, supply ~9,000 homes; €50M (R$350M) investment, completion by end-2026.
• 

  15 May 2026

  Genentech’s Tecentriq approved by FDA as ctDNA‑guided adjuvant therapy for MIBC

  FDA approves first ctDNA‑MRD‑guided adjuvant option for muscle‑invasive bladder cancer. IMvigor011: ctDNA+ patients had 36% reduced DFS risk and 41% reduced OS risk; Signatera CDx authorized.
• 

  15 May 2026

  Eni completes investment in Nouveau Monde Graphite

  US$70M subscription (of US$309.5M round) buys ~11.6% stake and board seat; secures graphite/anode material supply and supports Brindisi Gigafactory and supply-chain diversification.
• 

  15 May 2026

  Technip Energies awarded FNTP for Commonwealth LNG 9.5 Mtpa EPC

  FID enables full execution; scope: six identical modular SnapLNG trains to accelerate schedule, reduce costs and improve predictability, advancing modular LNG delivery models.
• 

  15 May 2026

  EnviTec Biogas: solid 2025; regulatory setbacks dent 2026, growth expected from 2027

  Total output +6.8% to €376.4M; revenues -7.4% to €312.6M; EBT €26.0M (prev €44.0M) after ~€8M provision; dividend suspended. 2026 guidance: revenues €330–370M, EBT €5–15M.
• 

  14 May 2026

  Ecovyst completes $100M Term Loan B add-on for INEOS Calabrian acquisition

  Issued at par and co‑terminus with a $397M loan, the add‑on carries SOFR+2.00% and will partly fund the Calabrian sulfur dioxide and derivatives purchase; closing expected by end‑Q2 2026.
• 

  14 May 2026

  Repsol: Refining is strategic for Spain and Europe

  Chairman urged removing investment barriers and securing supply amid Iran crisis. CEO forecasts 6–9% DPS growth to 2028, 30–40% of CFO for returns; AGM ok'd dividends, €350m buyback
• 

  14 May 2026

  OrganOx appoints Naoya Iwata CEO & President

  Effective June 1, 2026, he brings 20+ years at Terumo in sales, strategy and business development, including Chief of Staff experience, to scale commercial growth and NMP adoption.